CompletedNCT00238654Updated Apr 12, 2011

A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

An observational study in Multiple Sclerosis, sponsored by Teva Neuroscience, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.

Sponsored by Teva Neuroscience, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 257
Ages: 18 Years and older
Sex: All

Study summary

This study has patients responding to two sets of surveys that will tell their doctor or nurse about their readiness to begin self-injection. In addition, patients will have their self-injection observed and evaluated on up to three visits

Conditions studied

Multiple Sclerosis

Browse trials for

Multiple Sclerosis 3,524

In context

Multiple Sclerosis

3,524 studies on the registry are indexed under Multiple Sclerosis; 668 are open to participants now.

This study's enrollment of 257 is above the median of 100 across 1,034 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Teva Neuroscience, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Browse Teva Neuroscience, Inc. studies →All Teva Pharmaceutical Industries, Ltd. studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

RRMS patient with treatment-naïve or treatment-experienced

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or Female, 18 years of age or older, with diagnosis of RRMS
Naive to treatment or previously treated with an IFN.

Exclusion criteria

Exclusion Criteria:

Not eligible for treatment based on clinical criteria and current indication.
Unable to respond to surveys or provide informed consent.

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 257 participants (actual)

What researchers measure

Primary outcomes

Adherence of self-injection assessed by self-report at each follow-up visit
Time frame: 12 months

Study locations

No study locations are listed for this record.

Timeline

Tracking since Sep 25, 2026

Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered: Oct 12, 2005
First posted: Oct 13, 2005
Start: May 2003
Primary completionActual: Jul 2008
CompletionActual: Jul 2008
Last update: Apr 12, 2011

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Apr 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00238654
Lead sponsor: Teva Neuroscience, Inc.
First posted: Oct 13, 2005
Start date: May 2003
Primary completion: Jul 2008
Completion: Jul 2008
Last update: Apr 12, 2011

Study contacts

MerriKay Oleen-Burkey, Ph.D.

study director · Teva Neuroscience, Inc.

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Sclerosis →

Other studies from this sponsor

Teva Neuroscience, Inc. →

Start the discussion